MS
CATX icon

Maven Securities’s Perspective Therapeutics CATX Stock Holding History

Maven Securities’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,000
Closed -$167K – 1079
2021
Q1 		$167K Buy
+15,000
New +$227K 0.01% 945

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HPWM
Highland Private Wealth Management Bellevue, Washington $620M AUM 18.88% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Maven Securities's CATX Position: Q2 2021 in Review

Maven Securities sold out of Perspective Therapeutics (CATX) in Q2 2021, closing a stake of 15,000 shares — an estimated $167K sold.

Maven Securities first reported a position in CATX in Q1 2021 and held it in 1 quarter. The position peaked at $167K in Q1 2021. 48 funds tracked by Wall St. Rank hold CATX as of Q2 2021.

  • Maven Securities reported no remaining Perspective Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 15,000 Perspective Therapeutics shares in Q2 2021, an estimated $167K.
  • Maven Securities first reported a position in Perspective Therapeutics in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Perspective Therapeutics position peaked at $167K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.